Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies
MedComm · 2023-08 · 4 (4)
DOI: 10.1002/mco2.308 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 10.07.2023. Verfasst von Ziyu Ji und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Integrated Traditional Chinese and Western Medicine Southwest Medical University Luzhou Sichuan China. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 376 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
Osteosarcoma (OS) is a highly prevalent bone malignancy among adolescents, accounting for 40% of all primary malignant bone tumors. Neoadjuvant chemotherapy combined with limb‐preserving surgery has effectively reduced patient disability and mortality, but pulmonary metastases and OS cells' resistance to chemotherapeutic agents are pressing challenges in the clinical management of OS. There has been an urgent need to identify new biomarkers for OS to develop specific targeted therapies. Recently, the continued advancements in genomic analysis have contributed to the identification of clinically significant molecular biomarkers for diagnosing OS, acting as therapeutic targets, and predicting prognosis. Additionally, the contemporary molecular classifications have revealed that the signaling pathways, including Wnt/β‐catenin, PI3K/AKT/mTOR, JAK/STAT3, Hippo, Notch, PD‐1/PD‐L1, MAPK, and NF‐κB, have an integral role in OS onset, progression, metastasis, and treatment response. These molecular classifications and biological markers have created new avenues for more accurate OS diagnosis and relevant treatment. We herein present a review of the recent findings for the modulatory role of signaling pathways as possible biological markers and treatment targets for OS. This review also discusses current OS therapeutic approaches, including signaling pathway‐based therapies developed over the past decade. Additionally, the review covers the signaling targets involved in the curative effects of traditional Chinese medicines in the context of expression regulation of relevant genes and proteins through the signaling pathways to inhibit OS cell growth. These findings are expected to provide directions for integrating genomic, molecular, and clinical profiles to enhance OS diagnosis and treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Integrated Traditional Chinese and Western Medicine Southwest Medical University Luzhou Sichuan China.
- Department of Orthopaedics Affiliated Hospital of Putian University Putian Fujian China.
- Department of Physiology School of Basic Medical Science Southwest Medical University Luzhou Sichuan China.
- Department of Orthopaedics The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University Luzhou Sichuan China.
Förderung
- Natural Science Foundation of Fujian Province
Zitieren
APA
Ji, Z., Shen, J., Lan, Y., Yi, Q., & Liu, H. (2023). Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies. MedComm, 4(4). https://doi.org/10.1002/mco2.308
Vancouver
Ji Z, Shen J, Lan Y, Yi Q, Liu H. Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies. MedComm. 2023;4(4). doi:10.1002/mco2.308
BibTeX
@article{Ji2023,
author = {Ji, Ziyu and Shen, Jianlin and Lan, Yujian and Yi, Qian and Liu, Huan},
title = {Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies},
journal = {MedComm},
year = {2023},
volume = {4},
number = {4},
doi = {10.1002/mco2.308}
}
EUVIMED